Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction


Jun 16, 2015
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering

Nov 11, 2014
BioCardia®, Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients

Sep 15, 2014
CellProThera® and BioCardia® Partner on Phase II Trial to Study CellProThera’s Protheracytes® CD34+ Cells as Delivered by BioCardia’s Helix™ Transendocardial Delivery System

May 19, 2014
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System

May 7, 2014
RECARDIO Clinical Trial Doses First Patient

March 17, 2014
BioCardia® Receives CE Mark for Morph AccessPro™ Steerable Introducer

more news



We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 

These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.